Syneos Health Wins 2023 ViE Award
05 April 2023 - 9:30PM
Syneos Health® (Nasdaq:SYNH), a leading fully integrated
biopharmaceutical solutions organization, today announced it has
been awarded the Vaccine Industry Excellence Award for Best
Contract Research Organization (CRO). Presented at the 2023 World
Vaccine Congress in Washington, D.C., the award recognizes the
vaccine industry’s most outstanding efforts, accomplishments and
positive contributions of companies and individuals.
Syneos Health has an extensive range of industry-leading
expertise in bacteriology, virology, mycology, and associated
diseases and syndromes. In the past five years, the Company’s
Catalyst Vaccine Network sites have conducted more than 700 vaccine
studies, enrolling nearly 50,000 patients.
“The Syneos Health Global Vaccines Center of Excellence is a
diverse group of vaccine experts committed to working
collaboratively with our customers to create customized and
innovative solutions designed to overcome the unique challenges
vaccine sponsors face,” said Lynlee Burton, Vice President, Project
Management, Vaccine Segment Lead, Syneos Health. “Our unique
approach brings experts along the entire asset development
continuum together to navigate challenges and increase the
likelihood of regulatory approval to maximize commercial success.
We are honored to receive this award that acknowledges our
accomplishments in the vaccine sector.”
This year’s winners were selected by judges who voted for the
CRO they believe best demonstrates the range of services provided
in niche and core therapeutic areas, improvement or introduction of
new services, attention to and quality of relationships with
customers, reaching of milestones and ongoing outcomes, and
building and maintaining existing and long-term partnerships.
To learn more about how Syneos Health is accelerating
development in infectious disease and vaccine clinical trials,
visit
www.syneoshealth.com/therapeutic-expertise/therapeutic-areas/infectious-diseases-and-vaccines.
About Syneos HealthSyneos Health® (Nasdaq:SYNH)
is a leading fully integrated biopharmaceutical solutions
organization built to accelerate customer success. We translate
unique clinical, medical affairs and commercial insights into
outcomes to address modern market realities.
We bring together a talented team of professionals, who work
across more than 110 countries, with a deep understanding of
patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and
apply advanced business practices to speed our customers’ delivery
of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive
culture that cares for colleagues, customers, patients, communities
and the environment.
To learn more about how we are Shortening the distance
from lab to life®, visit syneoshealth.com
or subscribe to our podcast.
Investor Relations Contact:Ronnie SpeightSenior
Vice President, Investor Relations+1 919 745
2745 Investor.Relations@syneoshealth.com
Press/Media Contact:Gary GatyasExecutive
Director, External Communications+1 908 763
3428gary.gatyas@syneoshealth.com
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024